Wednesday, July 8, 2026

pharma · No medical condition. · Breast cancer

George Institute for

George Institute for clinical programs — 83 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Sydney, NSW 2042, AU HQ
1999 Founded
841 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Sydney, NSW 2042, AU
Founded
1999
Employees
841
Programs
406
Drugs
522
Patents
0
Intelligence · Clinical Programs

George Institute for projects

83 ClinicalTrials.gov programs sponsored by George Institute for.

George Institute for has 83 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

Page 1 of 2
  1. -

    The George Institute

    Acute lower Respiratory Tract Infection or acute rhinosinusitis

    approved small molecule active

    1 trial
  2. 2024/3873 CABOLD

    The George Institute

    Renal carcinoma

    approved small molecule active

    1 trial
  3. AB.OH.2025

    The George Institute

    Infectious diseases

    approved small molecule active

    1 trial
  4. ACETYLSALICYLIC ACID

    The George Institute

    Obstetrics – Preeclampsia

    approved small molecule active

    1 trial
  5. ADIPGEN

    The George Institute

    Knee Osteoarthritis

    approved small molecule active

    1 trial
  6. ALLERDOG

    The George Institute

    Allergic rhinitis due to dog allergy

    approved small molecule active

    1 trial
  7. AMOXICILINA NORMON 1000 mg Comprimidos EFG

    The George Institute

    Infective endocarditis

    approved small molecule active

    1 trial
  8. ANGELO

    The George Institute

    Obesity

    approved small molecule active

    1 trial
  9. Alirocumab, Placebo product for REGN727

    The George Institute

    Cardiac allograft vaculopathy in recent heart transplant recipients

    approved small molecule active

    1 trial
  10. Amiodarone hydrochloride 200 mg tablets

    The George Institute

    Persistent atrial fibrillation

    approved small molecule active

    1 trial
  11. Avian_inf_vacc_THL20

    The George Institute

    Avian influenza and seasonal influenza

    approved small molecule active

    1 trial
  12. BIMERVAX LP.8.1 emulsion for injection COVID... for COVID-19 infection

    The George Institute

    COVID-19 infection

    approved small molecule active

    1 trial
  13. BUDESONIDE

    The George Institute

    Chronic obstructive pulmonary disease (COPD)

    approved small molecule active

    1 trial
  14. CARDIOPLEGIA SOLUTIONS

    The George Institute

    Cardiovascular pathology

    approved small molecule active

    1 trial
  15. CARFLECT IV

    The George Institute

    Idiopathic ventricular arrhythmias

    approved small molecule active

    1 trial
  16. CEFOSPROST

    The George Institute

    Acute bacterial prostatitis

    approved small molecule active

    1 trial
  17. CITISILONG

    The George Institute

    Active smokers

    approved small molecule active

    1 trial
  18. CLEAN+

    The George Institute

    colorectal cancer early detection

    approved small molecule active

    1 trial
  19. CoLeBu

    The George Institute

    Hip fracture

    approved small molecule active

    1 trial
  20. Cyclogest 400 mg óvulos

    The George Institute

    Infertility

    approved small molecule active

    1 trial
  21. DARBEPOETIN ALFA

    The George Institute

    hepatic trasplant

    approved small molecule active

    1 trial
  22. DOBUTAMINE , LEVOSIMENDAN

    The George Institute

    Heart failure patients with depressed left ventricular ejection fraction

    approved small molecule active

    1 trial
  23. ENDORET-PRGF

    The George Institute

    pterygium

    approved small molecule active

    1 trial
  24. ENRICH-AF

    The George Institute

    High risk atrial fibrillation patients with previous intracranial hemorrhage

    approved small molecule active

    1 trial
  25. EPHIC-DIA2

    The George Institute

    Type 2 Diabetes Mellitus

    approved small molecule active

    1 trial
  26. Eliquis film-coated tablets for Left ventricular thrombosis., A…

    The George Institute

    Left ventricular thrombosis., Acute mycocardial infarction (AMI)

    approved small molecule active

    1 trial
  27. FOSFOMYCIN

    The George Institute

    Uncomplicated urinary tract infection (uUTI)

    approved small molecule active

    1 trial
  28. Ferinject 50 mg/ml dispersión inyectable y para perfusión

    The George Institute

    Anemia in patients with chronic ischemia of the lower limb ischemia

    approved small molecule active

    1 trial
  29. Ferinject 50 mg/ml dispersión inyectable y para perfusión

    The George Institute

    Acute coronary syndrome

    approved small molecule active

    1 trial
  30. GadoCrohn

    The George Institute

    Perianal fistula associated with Crohn's disease

    approved small molecule active

    1 trial
  31. Gardasil 9 suspension for Evaluation of the reduction of…

    The George Institute

    Evaluation of the reduction of HPV infectivity and transmission before and after vaccination with 9vHPV

    approved small molecule active

    1 trial
  32. HCB.2021.1309

    The George Institute

    Coronary artery chronic total occlusion

    approved small molecule active

    1 trial
  33. HEBRO-001

    The George Institute

    Hypertension

    approved small molecule active

    1 trial
  34. HUMAN SERUM ALBUMIN, SODIUM CHLORIDE

    The George Institute

    descompensated hepatic cirrosis

    approved small molecule active

    1 trial
  35. HYDROCORTISONE PH. EUR., HYDROCORTISONE PH. EUR.

    The George Institute

    Adrenal hyperplasia or isolated primary adrenal insufficiency or panhypopituitarism (secondary or tertiary adrenal insufficiency).

    approved small molecule active

    1 trial
  36. ICI22/00054

    The George Institute

    patients who are requested a colonoscopy for any indication and are under antiplatelet treatment (except ASA) or anticoagulant treatment

    approved small molecule active

    1 trial
  37. IIBSP-FAS-2020-120

    The George Institute

    Complicated acute appendicitis

    approved small molecule active

    1 trial
  38. IIBSP-HOP-2021-01

    The George Institute

    Acute Ischemic Stroke

    approved small molecule active

    1 trial
  39. IIBSP-OXI-2022-124

    The George Institute

    Borderline Personality Disorder.

    approved small molecule active

    1 trial
  40. IJG-PREMI-2024

    The George Institute

    Migraine

    approved small molecule active

    1 trial
  41. INDOCYANINE GREEN

    The George Institute

    Patients with liver tumors that will undergo minimally invasive liver surgery

    approved small molecule active

    1 trial
  42. INFLUENZA for Influenza, Immunity against inf…

    The George Institute

    Influenza, Immunity against influenza

    approved small molecule active

    1 trial
  43. Iomeron 400 mgI/ml solution for injection

    The George Institute

    Thoracic neoplasm

    approved small molecule active

    1 trial
  44. KTI2023

    The George Institute

    Graft pyelonephritis in kidney transplant recipients

    approved small molecule active

    1 trial
  45. LINEZOLID, LINEZOLID

    The George Institute

    Sepsis

    approved small molecule active

    1 trial
  46. LIVTENCITY 200 mg film-coated tablets.

    The George Institute

    Transplant patients with high recurrent Epstein-Barr infection

    approved small molecule active

    1 trial
  47. LUTI Study

    The George Institute

    Infertility

    approved small molecule active

    1 trial
  48. MAMBO-II

    The George Institute

    Migraine

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does George Institute for have?

83 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.